Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cadence Design Systems Inc (CDNS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cadence Design Systems Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Cadence Design Systems Inc trades at $392.81 (market cap $105.96B). The key difference: Cadence Design Systems Inc is far larger — about 2.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Cadence Design Systems Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CDNS | |
|---|---|---|
Market Cap | $39.89B | $105.96B |
Sector | Health | Technology |
52-Week High | $491.22 | $416.39 |
52-Week Low | $278.09 | $265.66 |
Enterprise Value | $38.15B | $107.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Cadence Design Systems (CDNS) trades at $384.17, down 0.46% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with consistent revenue growth from $3.6B in 2022 to $5.3B in 2025, and has beaten earnings estimates for three consecutive quarters. Analyst sentiment remains overwhelmingly positive with 83.87% buy ratings and a $395.88 consensus price target, representing 3% upside potential.
The outlook for CDNS remains favorable given its strategic position in semiconductor design software and AI-driven demand, though elevated valuation ratios (P/E 89.55, P/S 18.99) warrant caution. Key risks include semiconductor cycle volatility and competitive pressures, but strong cash flow generation and institutional support provide stability for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →
